Zolbetuximab as a gastric lineage-directed immunotherapy: mechanistic rationale and translational evidence in CLDN18.2-positive gastroesophageal adenocarcinoma

Kristian Egebjerg; F. Lordick; Lisa L. Liu; Nanna Blücher Dahlgaard; Morten Mau-Sørensen

doi:10.1080/14737140.2026.2615855

January 11, 2026Expert Review of Anticancer Therapy

Zolbetuximab as a gastric lineage-directed immunotherapy: mechanistic rationale and translational evidence in CLDN18.2-positive gastroesophageal adenocarcinoma

View at Publisher

Ask AI

Bookmark

Share

Key Points

The study aims to explore zolbetuximab's efficacy as a targeted treatment in specific cancer types.
Investigated zolbetuximab as a targeted cytolytic antibody.
Outlined future studies involving combinations with checkpoint blockade.
Focused on refining biomarkers related to the therapy.
Zolbetuximab shows potential as a novel treatment method.
Recommendations for further testing combinations with existing therapies.
Emphasis on understanding resistance mechanisms for better outcomes.

Implication

Investigational therapy evaluates outcomes in CLDN18.2-positive gastroesophageal adenocarcinoma, indicating future research directions.

Abstract

Zolbetuximab exemplifies a novel therapeutic class which can be classified as targeted cytolytic antibodies. Future work should test combinations with checkpoint blockade, refine biomarkers and define resistance mechanisms.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Egebjerg et al. (2026) studied this question.

synapsesocial.com/papers/696719b10a9733890c4ee16d https://doi.org/10.1080/14737140.2026.2615855

View at Publisher

Ask AI

Bookmark

Share

Zolbetuximab as a gastric lineage-directed immunotherapy: mechanistic rationale and translational evidence in CLDN18.2-positive gastroesophageal adenocarcinoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Zolbetuximab as a gastric lineage-directed immunotherapy: mechanistic rationale and translational evidence in CLDN18.2-positive gastroesophageal adenocarcinoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading